---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-125336"
form_type: "8-K"
ticker: "CLYM"
cik: "0001768446"
company_name: "Climb Bio, Inc."
filed_at: "2024-11-12T23:59:59+00:00"
generated_at: "2026-05-30T02:05:00.807045+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Climb Bio Q3 net loss $8.9M; cash $217.9M through 2027; FDA IND cleared for SLE trial

## Summary
- Net loss $8.9M for Q3 2024 vs $4.0M Q3 2023; R&D expenses $6.2M, G&A $5.5M.
- Cash $217.9M as of Sep 30, 2024; expected to fund operations through 2027.
- FDA cleared IND for budoprutug in SLE; Phase 1b trial planned H1 2025.
- Appointed Doug Williams as Chair of Board; Gary Hao as VP of CMC.
- Phase 1b pMN data showed 60% complete remission; Phase 2 ITP trial planned H1 2025.

## SEC filing metadata
- accession: 0000950170-24-125336
- form_type: 8-K
- ticker: CLYM
- cik: 0001768446
- company_name: Climb Bio, Inc.
- filed_at: 2024-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1768446/000095017024125336/0000950170-24-125336-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1768446/000095017024125336/clym-20241112.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-125336
- JSON: https://secwatch.observer/filing/0000950170-24-125336.json
- Plain text: https://secwatch.observer/filing/0000950170-24-125336.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.